A Review on Emerging Impact of Antitubercular Activity of 1,2,4-Triazole Derivatives

Abstract

The present review aims to summarize the antitubercular profile of 1,2,4-triazole, one of the emerging entitled and most sought scaffold with a wide spectrum of biological and pharmacological activities. A systematic review of literature on ‘Heterocycles’, establishes the fact that 1,2,4-triazoles and their derivatives exhibit diverse activities. The 1,2,4-triazole core is found in therapeutically significant drugs and many new ones are in the pipeline. ‘Triazole pharmacophore’ has replaced the widely used ‘imidazole’ as ‘systemically integral azole’ by connecting synchronicity with serendipity. Triazoles are penetratingly studied as ‘diverse therapeutic agents’, due to the improved efficacy and reduced side effects. The extensive anthology of work carried out in the last two decades on 1,2,4-triazole moiety will provide imminent scope for the development of novel potential drugs having better efficacy selectivity and reduced toxicity.

Synthesis and biological evaluation of novel hybrid compounds bearing pyrazine and 1,2,4-triazole analogues as potent antitubercular agents

“…Pyrazine and 1,2,4-triazole analogues, well-known for their diverse pharmacological properties, have garnered substantial attention as potential building blocks for such hybrid compounds. 5,6 Pyrazinamide serves as a primary pharmacotherapeutic agent in the treatment of tuberculosis, commonly employed in conjunction with other anti-TB medications. Its robust anti-TB efficacy plays a pivotal role in abbreviating the duration of tuberculosis therapy.…”